PortfoliosLab logo
Bionomics Limited (BNOX)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US09063M2052

CUSIP

09063M205

IPO Date

Dec 16, 2021

Highlights

Market Cap

$4.95M

EPS (TTM)

-$14.32

Total Revenue (TTM)

$761.65K

Gross Profit (TTM)

-$4.94M

EBITDA (TTM)

-$6.23M

Year Range

$2.12 - $15.24

Target Price

$9.74

Short %

1.23%

Short Ratio

0.13

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart


Loading data...

Returns By Period


BNOX

YTD

N/A

1M

N/A

6M

N/A

1Y

N/A

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

-0.64%

1M

8.97%

6M

-2.62%

1Y

11.90%

5Y*

15.76%

10Y*

10.69%

*Annualized

Monthly Returns

The table below presents the monthly returns of BNOX, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202554.52%-5.47%46.06%
2024-34.66%28.23%-16.94%-7.77%-11.58%-8.69%-1.89%-14.62%-31.63%-54.70%50.80%-4.75%-80.69%
2023-13.98%-25.00%-13.33%-13.46%-1.33%-0.90%-25.45%9.76%50.00%-8.89%-46.34%12.12%-68.17%
2022-10.53%-9.16%-16.67%-8.24%-3.08%-7.54%-6.29%17.56%-18.63%31.67%-15.15%-33.57%-62.95%
2021-14.80%-14.80%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of BNOX is 36, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of BNOX is 3636
Overall Rank
The Sharpe Ratio Rank of BNOX is 3434
Sharpe Ratio Rank
The Sortino Ratio Rank of BNOX is 5959
Sortino Ratio Rank
The Omega Ratio Rank of BNOX is 6060
Omega Ratio Rank
The Calmar Ratio Rank of BNOX is 1010
Calmar Ratio Rank
The Martin Ratio Rank of BNOX is 1717
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Bionomics Limited (BNOX) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


There isn't enough data available to calculate the Sharpe ratio for Bionomics Limited. This metric is based on the past 12 months of trading data. Please check back later for updated information.


Loading data...

Dividends

Dividend History


Bionomics Limited doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading data...

Worst Drawdowns

The table below displays the maximum drawdowns of the Bionomics Limited. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Bionomics Limited was 98.70%, occurring on Nov 4, 2024. The portfolio has not yet recovered.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-98.7%Dec 17, 2021724Nov 4, 2024

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading data...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Bionomics Limited over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of Bionomics Limited, comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 100.0% positive surprise.


-100.00-80.00-60.00-40.00-20.000.00AprilJulyOctober2021AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJuly
-0.05
-0.58
Actual
Estimate

Valuation

The Valuation section provides an overview of how Bionomics Limited is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for BNOX relative to other companies in the Biotechnology industry. Currently, BNOX has a P/S ratio of 1,105.5. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for BNOX in comparison with other companies in the Biotechnology industry. Currently, BNOX has a P/B value of 0.6. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items